You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康華生物(300841.SZ)上修業績預告:上半年淨利預增112.33%-118.23%
格隆匯 07-08 20:23

格隆匯 7 月 8日丨康華生物(300841.SZ)披露2020年半年度業績預告修正公告,修正前,公司預計2020年上半年歸屬於公司股東的淨利潤約為1.61億元至1.69億元,較上年同期增長約89.92%-99.36%;扣除非經常性損益後歸屬於公司股東的淨利潤約為1.6億元-1.68億元,較上年同期的增長幅度為90.11%-99.62%。

修正後,預計歸屬於上市公司股東的淨利潤1.8億元-1.85億元,同比增長112.33%-118.23%;扣除非經常性損益後歸屬於上市公司股東的淨利潤1.79億元-1.84億元,同比增長112.69%-118.63%。

業績修正原因為:1、公司核心產品凍幹人用狂犬病疫苗(人二倍體細胞)因市場需求等因素,產品銷量增加。2、疫情期間,在嚴格遵守國家疫情防控要求、保證人員安全的前提下,公司保障復工復產順利進行,疫苗生產和銷售未受疫情影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account